This is of special importance as patients with KRAS and NRAS mutations do not respond well to EGFR inhibitors panitumumab and cetuximab35, which may mean that patient CRC-005 that exhibited an EGFR amplification in the metastasis but also carried an ARHGEF33 mutation, may not respond to EGFR inhibitor therapy. This evidence concerns the gene EGFR and colorectal carcinoma.